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A B S T R A C T   
Background: Emu Oil (EO) previously demonstrated therapeutic potential in a mouse model of colitis-associated 
CRC (CA-CRC). Saireito, a traditional Japanese medicine, has not been investigated in CA-CRC. 
Aim: To determine whether EO and Saireito could be therapeutic in an azoxymethane (AOM)/dextran sulphate 
sodium (DSS) model of CA-CRC. 
Methods: Female C57BL/6 mice were assigned to groups (n = 10/group); 1) saline control, 2) saline+Saireito, 3) 
saline+EO, 4) saline+EO/Saireito, 5) AOM/DSS control, 6) AOM/DSS+Saireito, 7) AOM/DSS+EO and 8) AOM/ 
DSS+EO/Saireito. Mice were intraperitoneally injected with saline or AOM (7.4 mg/kg) on day 0 and underwent 
three DSS/water cycles (2%w/v DSS for 7 days, 14 days water). Mice were orally-gavaged with either water (80 
µL), Saireito (80 µL), EO (80 µL) or EO/Saireito (160 µL; 80 µL EO + 80 µL Saireito) thrice weekly. Daily 
bodyweight and disease activity index (DAI) were recorded and colonoscopies performed on days 20, 41 and 62. 
Mice were euthanized on day 63. p < 0.05 was considered statistically significant. 
Results: AOM/DSS induced significant bodyweight loss throughout the trial (max − 36%), which was attenuated 
by Saireito (max +7%), EO (max +5%) and EO/Saireito (max +14%; p < 0.05). AOM/DSS increased DAI 
compared to saline controls (p < 0.05), which was reduced by Saireito, EO and EO/Saireito (p < 0.05). All 
treatments reduced colonoscopically-assessed colitis severity (days 20 and 41; p < 0.05). EO/Saireito further 
decreased colitis severity compared to Saireito and EO alone (day 20; p < 0.05). Finally, EO and EO/Saireito 
resulted in fewer colonic tumours compared to AOM/DSS controls (p < 0.05). 
Conclusion: Combined EO and Saireito reduced disease and tumour development in AOM/DSS mice, suggesting 
therapeutic potential in CA-CRC.   
1. Introduction 
Ulcerative colitis (UC) is a debilitating and lifelong inflammatory 
bowel disease (IBD) that presents as continuous damage and inflam-
mation of the large intestine [1]. IBD pathogenesis is complex and not 
fully understood, however, a combination of immunological dysregu-
lation, environmental, diet, lifestyle and psychological wellbeing can 
contribute to disease onset [1,2]. Furthermore, 8–14% of UC patients 
have a family history of IBD, highlighting a genetic predisposition. UC 
has historically been most common in Western societies, although 
prevalence is now increasing in Asian and Latin American countries [2]. 
There is currently no cure for UC and patients must resort to 
anti-inflammatory and immunomodulatory drugs and potent steroids to 
manage symptoms and maintain remission [2]. Unfortunately, 15% of 
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UC patients will require surgery to remove segments of the colon, or 
sometimes the entire colon, approximately 20 years following diagnosis 
[2]. Furthermore, cancer is the major cause of mortality for IBD patients, 
with UC patients being at an increased risk of developing 
colitis-associated colorectal cancer (CA-CRC) due to uncontrolled and 
long-term chronic inflammation [3,4]. 
Recently, a disruption of the epithelial barrier and intestinal micro-
bial biodiversity has been a focus of UC and CA-CRC research. Treat-
ments are now centring on restoring intestinal integrity, impeding 
migration of immune cells and controlling microbial populations via 
transplants from healthy donors [2,5,6]. Naturally-sourced compounds 
derived from animals or plants have also gained interest as adjunct 
therapies for gastrointestinal conditions [7–10]. 
Emu Oil, derived from the subcutaneous and retroperitoneal adipose 
tissue of the native Australian Emu (Dromaius novaehollandiae) has been 
investigated as an orally-administered anti-inflammatory agent in pre- 
clinical settings of gastrointestinal disorders including UC, Crohn’s 
disease, intestinal mucositis and CA-CRC [11–21]. Traditionally, Emu 
Oil has been used topically by Indigenous Australian people to alleviate 
pain and promote wound healing [12]. Although the mechanisms are 
still not fully understood, the anti-inflammatory and anti-oxidant 
properties of Emu Oil are attributed to the fatty acid composition and 
the uncharacterised 2% non-triglyceride fraction of the oil [7,12,22]. 
Previously in a study of CA-CRC in mice, Emu Oil application resulted in 
decreased clinical indicators of disease and reduced small colonic tu-
mours compared to disease controls over a 9-week experimental period 
[14]. However, the overall tumour number was unaffected by Emu Oil 
treatment. Combining Emu Oil with other naturally-sourced compounds 
could therefore be one means to increase its potency and elicit a more 
pronounced effect on tumour development in pre-clinical CA-CRC. 
Kampo medicines are Traditional Japanese Herbal formulations that 
comprise various ratios of plant-based constituents. Kampo is widely 
accepted in Japan with 148 Kampo extractions being covered by na-
tional health insurance and approximately 85% of practitioners regu-
larly prescribing these traditional medicines [23]. Kampo is used in 
conjunction with Western medicines to enhance immunity and relieve 
adverse drug reactions for a plethora of conditions including gastroin-
testinal diseases and cancer [24]. Specifically, Daikenchuto and Juzen-
taihoto have been widely investigated in pre-clinical settings of UC and 
CRC, whereby these Kampo formulations inhibited tumour growth, 
decreased levels of inflammatory cytokines (TNF-α and IL-1β) and 
increased the abundance of natural killer cells [24–26]. Saireito, a 
combination of two Kampo medicines (Shosaikoto and Goreisan) is 
composed of 12 herbs; Bupleuri radix, Pinelliae tuber, Alismatis rhizoma, 
Scutellariae radix, Ginseng radix, Poria, Polyporus, Astractylodis lanceae 
rhizoma, Zizyphi fructus, Glycyrrhizae radix, Cinnamomi cortex and Zingi-
beris rhizome. Saireito has displayed anti-inflammatory and immuno-
modulatory effects in clinical and experimental investigations of UC, 
chronic hepatitis and rheumatoid arthritis [27–29]. However, Saireito is 
yet to be investigated in the setting of CA-CRC. 
The aim of the current study was to investigate whether Emu Oil and 
Saireito in combination could reduce the severity of chronic colitis and 
inhibit the subsequent development of colorectal tumours in an azoxy-
methane (AOM)/ dextran sulphate sodium (DSS) mouse model of CA- 
CRC. Furthermore, the anti-inflammatory action of Emu Oil and 
Kampo medicines is well understood; however, the mechanism of action 
and effect on inflammatory cytokines has not yet been defined, 
prompting further analyses in vitro. 
2. Materials and methods 
2.1. Dendritic cell maturation and ELISA 
The potential anti-inflammatory effect of Emu Oil and/or Saireito 
was determined using dendritic cell (DC) model as described previously 
(Hardardottir, Olafsdottir et al. [30]). In short, CD14+ monocytes were 
isolated from peripheral blood mononuclear cells that were obtained 
from buffy coat from healthy blood donors (Blood Bank, Landspitali - the 
National University Hospital of Iceland, Reykjavik, Iceland) using CD14 
Microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). The 
CD14+ monocytes were cultured in RPMI medium supplemented with 
10% foetal calf serum (FCS) (both from Gibco, Thermo Fisher Scientific, 
Paisley, UK) and 12.5 ng/ml interleukin (IL)-4 and 25 ng/ml 
granulocyte-macrophage colony-stimulating factor (GM-CSF; both from 
R&D Systems, Bio-techne, Abingdon, UK) for differentiation into 
immature dendritic cells (imDC). The 48-well tissue culture plate was 
incubated at 37 ◦C with 5% CO2 and 100% humidity for seven days. On 
day seven, the imDCs were harvested and activated into matured den-
dritic cells (mDC) by culturing them in 48-well culture plates for 2 days 
in RPMI medium supplemented with 10% FCS and 10 ng/ml IL-1β, 50 
ng/ml tumour necrosis factor (TNF)-α (both from R&D Systems, 
Bio-techne, Abingdon, UK), and 500 ng/ml lipopolysaccharides (LPS) 
(Sigma-Aldrich, trading as Merck, Darmstadt, Germany). At the same 
time 10 µL of 100 µg/ml Saireito, sonicated Emu Oil and combined Emu 
Oil/Saireito were added to three wells each (final concentration 2 
µg/ml) and three wells left without addition. mDCs were harvested and 
centrifuged (300 g for 10 min at 4 ◦C) and supernatant collected and 
stored at − 80 ◦C until used [30]. 
The maturation of DCs was determined by measuring the concen-
tration of the pro-inflammatory cytokine IL-12p40 and anti- 
inflammatory cytokine IL-10 in the cell supernatants using DuoSet 
ELISA kits (R&D Systems) according to the manufacturer’s instructions. 
Results are presented as secretion index (SI), indicating the concentra-
tion of the cytokine in supernatant from cultured DCs cultured with 
Saireito, sonicated Emu Oil and combined Emu Oil/Saireito, divided by 
the concentration of the cytokine in supernatant from DCs cultured 
without any addition. 
2.2. Experimental timeline 
Animal studies were conducted in compliance with the Australian 
Code for the Care and Use of Animals for Scientific Purposes and were 
approved by the Animal Ethics Committees of The University of Ade-
laide and Children, Youth and Women’s Health Service (AE 1079/3/21). 
Female C57BL/6 mice (C57BL/6JArc, n = 80) were sourced from the 
Animal Resource Centre (Perth, Western Australia, Australia) at 8 weeks 
of age and were group-housed in standard open-top cages (poly-
propylene; 470 mm x 175 mm x 120 mm; Crestware Industries) at room 
temperature with a light/dark cycle of 14:10 h. Mice were fed standard 
mouse chow (meat-free mouse diet; Specialty Feeds, Glen Forrest, 
Western Australia, Australia) and were provided with enrichment items 
including shredded paper, polycarbonate ‘houses’ and cardboard toilet 
paper rolls for the duration of the trial. Plain drinking water was also 
provided ad libitum throughout the trial, except when precluded by 
group allocation. 
Mice (n = 10/group) were randomly allocated to eight treatment 
groups (displayed as intraperitoneal (i.p.) injection + ad libitum + oral 
gavage); 1) Saline + Water + Water, 2) Saline + Water + Saireito, 3) 
Saline + Water + Emu Oil, 4) Saline + Water + combined Emu Oil and 
Saireito (Emu Oil/Saireito), 5) AOM + DSS + Water, 6) AOM + DSS +
Saireito, 7) AOM + DSS + Emu Oil and 8) AOM + DSS + Emu Oil/ 
Saireito. On day 0, all mice were injected (i.p.) with either saline or the 
carcinogen AOM (7.4 mg/kg; Sigma-Aldrich, Castle Hill New South 
Wales, Australia) and underwent three DSS/water cycles, each 
comprising of seven days DSS (2%w/v; 2 g/100 ml distilled water; MP 
Biomedicals LLC, Santa Ana California, USA) followed by 14 days of 
plain water recovery. Starting immediately, all mice were administered 
thrice weekly via oral gavage with 80 µL of either water, Saireito (1 g/kg 
bodyweight of mouse; Tsumura & Co., Tokyo, Japan), Emu Oil (100% v/ 
v; Emu Tracks, Marleston, South Australia, Australia) or a combination 
of Emu Oil and Saireito (160 µL; 80 µL Emu Oil + 80 µL Saireito) for the 
duration of the trial. All animals were euthanized on day 63 via CO2 
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asphyxiation and cervical dislocation. Blood was collected via cardiac 
puncture from groups 1 and 5–8 for intestinal permeability analyses. 
Visceral organs (heart, liver, lungs, spleen, thymus, kidney, stomach and 
caecum) were weighed and gastrointestinal organs (small and large in-
testine) measured and weighed. Sections of the proximal and distal 
colon were also collected for histological analysis. 
2.3. Daily measurements 
Bodyweight and disease activity index (DAI) were measured daily 
during routine morning monitoring over the experimental period. DAI 
was calculated from bodyweight loss, general condition, stool consis-
tency and rectal bleeding as described [11]. Each parameter was scored 
from 0 to 3 with increasing severity and then totalled to calculate the 
DAI score for each mouse on each day, with a maximum obtainable score 
of 12. 
2.4. Colonoscopy 
At the end of each three-week DSS/water cycle (days 20, 41 and 62), 
disease progression was monitored via colonoscopy using a high reso-
lution colonoscope (Karl Storz, 1.9 mm outer diameter, Tuttlingen, 
Germany). Mice were individually placed on a heating pad and anes-
thetised using isoflurane inhalant (AbbVie Pty Ltd, Mascot New South 
Wales, Australia) for the duration of the colonoscopy procedure. 
Immediately following the procedure, mice were transferred to a re-
covery cage on a heating pad and closely and continuously monitored 
until their behaviour returned to normal. Mice were then returned to 
their home cage. Videos obtained from the colonoscopy procedures were 
subsequently scored in a blinded fashion for colitis severity and tumour 
development as described by Becker et al. [31]. Colitis severity was 
calculated from five parameters (scored 0–3 with increasing severity) 
including, thickening of the colon, vasculature pattern, fibrin, granu-
larity of the mucosal surface and stool consistency and summed for a 
total colitis severity score, with a maximum attainable score of 15 [31]. 
Colonic tumours were also counted from colonoscopy videos for each 
mouse at each time-point. 
2.5. Burrowing analyses 
Burrowing behaviour was analysed during the experimental period 
as a measure of wellbeing and affective state [32]. At baseline (day − 1) 
and at the end of each DSS/water cycle (days 19, 40 and 61), nearing 
their dark cycle, mice were placed in the dark for at least one hour to 
acclimatize. In the dark, mice were then placed in individual cages 
containing an attached burrow with 400 g of pre-weighed pebbles (400 
g; kitty litter ‘pebbles’; Black and Gold, Australian Asia/Pacific Whole-
salers Pty Ltd, Australia). Mice were then left to burrow for an hour. 
After this time, mice were removed from the burrowing cages and 
burrows were re-weighed to determine the amount burrowed for each 
mouse at each time-point. 
2.6. Nesting behaviour 
Nest building is a normal behaviour that is carried out by mice in 
their home cage. Mice were provided with shredded paper and tissues in 
their home cage and nesting was analysed twice per week (every 3–4 
days), 24 h after home cages were changed and cleaned. Scores of 0 or 1 
were determined for each treatment group at each time-point, where 
0 indicated no nest was built and 1 represented positive nesting 
behaviour [33,34]. 
2.7. Intestinal permeability (FITC-dextran assay) 
Three hours prior to sacrifice, mice from groups 1 and 5–8, were 
orally-gavaged with a 500 mg/kg dose of fluorescein isothiocyanate 
(FITC)-dextran (mol wt 4000, 75 mg/ml; Sigma, Castle Hill, New South 
Wales, Australia). Blood was then collected at kill via cardiac puncture. 
Samples were centrifuged (11,000 g at 23 ◦C) for 12 min and serum 
collected. Serum samples were diluted 1:3 with 0.2 M PBS and FITC- 
dextran was quantified using a BioTek Synergy Mx Microplate Reader 
(BioTek, Winooski, Vermont, USA) and Gen5 version 2.00.18 software 
relative to a standard curve (0.001–100 μg/ml). 
2.8. Tumour photographs 
At time of kill, colons were removed and opened longitudinally to 
visualise tumours. Photographs of longitudinally-opened mouse colons 
(Canon 5D Mark IV with 17–40 mm lens) were analysed in a blinded 
fashion using Olympus Soft Imaging Solutions GmbH computer software 
analysis version 5.2 (Tokyo, Japan). The number of tumours was 
determined and categorised into sizes as described previously [14,17]. 
Colonic tumours with a diameter < 2 mm were determined as ‘small’, 
2–3 mm as ‘medium’ and ‘large’ tumours were those with a diameter >
3 mm. 
2.9. Histological analysis 
Sections of the proximal and distal colon were routinely processed 
and embedded in paraffin wax following collection. Section (4µm) were 
then stained with haematoxylin and eosin (H&E) and mounted on plain 
glass microscope slides. Histologically-assessed damage severity was 
assessed in a blinded-fashion using an Olympus BH-2 light microscope 
(Olympus Corporation, Tokyo, Japan) as previously described [35]. Six 
parameters including goblet cell reduction, crypt and crypt cell disrup-
tion, polymorphonuclear infiltration and thickening/oedema of the 
submucosa and muscularis externa were scored from 0 to 3 with 
increasing severity for four cross sections of colonic tissue per mouse. 
Median scores for each parameter were then calculated and summed to 
determine a final severity score per mouse per colonic section, with a 
maximum attainable score of 18. 
2.10. Statistical analyses 
Statistical analyses were completed using SPSS, version 25 for Win-
dows (SPSS Inc. Chicago, Illinois, USA). Data were tested for normality 
using a Shapiro–Wilk test. Bodyweight, DAI, burrowing activity, 
colonoscopically-assessed colitis score and tumour number were ana-
lysed by repeated measures ANOVA with least significance difference 
(LSD) to compare among and within a group. ELISA results were ana-
lysed by two samples t-test (assuming equal variance) at a 95% confi-
dence interval. Nesting behaviour was analysed with a non-parametric 
Kruskal-Wallis test. FITC-dextran data were logarithmically transformed 
and analysed using linear regression. Organ data and histologically- 
assessed severity scores were analysed using a one-way ANOVA with a 
Tukey’s post hoc test. For all analyses, p < 0.05 was considered statis-
tically significant. 
3. Results 
3.1. Cytokine secretion by dendritic cells in vitro 
Culturing dendritic cells in the presence of Emu Oil or in the presence 
of the combination of Emu Oil and Saireito decreased their secretion of 
IL-12p40 compared to that when they were cultured in the absence of 
the nutraceuticals (p < 0.05; Fig. 1). However, culturing dendritic cells 
in the presence of Saireito alone did not significantly impact their IL- 
12p40 secretion compared to the negative control. None of the treat-
ments affected dendritic cell secretion of IL-10 (Fig. 1). 
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3.2. Bodyweight 
In normal mice, Saireito (day 63) and Emu Oil (day 18) slightly 
increased bodyweight compared to saline controls, with no effect 
exhibited by the treatments on other days (p < 0.05; Fig. 2a). AOM/DSS 
induced significant bodyweight loss on most days of the experimental 
trial compared to saline controls (days 4–16, 25–33, 46–56 and 61; 
p < 0.05; Fig. 2b). Saireito-administration increased bodyweight of 
AOM/DSS mice on day 50 and slightly decreased bodyweight on days 41 
and 43 compared to AOM/DSS controls (p < 0.05; Fig. 2c). Additionally, 
Emu Oil increased bodyweight on days 15, 57, 58, 62 and 63 of the trial 
compared to AOM/DSS controls (p < 0.05; Fig. 2c). However, Emu Oil 
slightly decreased bodyweight of AOM/DSS mice on days 41–43 
compared to AOM/DSS controls (p < 0.05; Fig. 2c). The combination of 
Emu Oil/Saireito attenuated bodyweight loss in AOM/DSS mice on days 
6–12, 29–32 and 47–51 compared to AOM/DSS controls (p < 0.05; 
Fig. 2c). Finally, the combination of Emu Oil and Saireito further 
attenuated bodyweight loss of AOM/DSS mice compared to Saireito 
along (days 6–11, 29–32, 34, 37, 38, 43, 47 and 48) and Emu Oil alone 
(days 7–18, 20–21, 25–27, 30–35, 38, 46–58 and 60–63; p < 0.05; 
Fig. 2c). 
3.3. DAI 
In normal mice, administration of Saireito (day 48), Emu Oil (day 57) 
and Emu Oil/Saireito (day 6) slightly increased DAI scores compared to 
saline controls (p < 0.05; Fig. 3); however, this result was not consis-
tently observed throughout the nine-week trial. As expected, AOM/DSS 
controls displayed significantly increased DAI scores compared to saline 
controls at most time-points (days 4–19, 21–33, 35–36 and 38–63; 
p < 0.05; Fig. 3). Saireito (days 6, 9, 12, 13, 15, 17, 19, 20, 22, 24, 25, 
27, 29–32, 39, 40, 42, 44–46, 50–56, 59–61 and 63) and Emu Oil (days 
6, 9, 12, 16, 17, 19, 21, 22, 25, 27–29, 31, 32, 39, 40, 44–47, 51, 53, 54, 
56 and 59–63) significantly decreased DAI scores of AOM/DSS mice, 
compared to AOM/DSS controls (p < 0.05; Fig. 3). Moreover, the 
combination of Emu Oil/Saireito in AOM/DSS mice decreased DAI 
scores in comparison with AOM/DSS controls on days 5–32, 34, 36–40, 
42–57 and 59–63 (p < 0.05; Fig. 3). Finally, the Emu Oil/Saireito 
combination further decreased DAI scores compared to Saireito alone 
(days 4, 6–10, 24–26, 28, 32, 34, 43 and 46–48) and Emu Oil alone 
(7–10, 15, 18, 23–26, 30, 38, 40, 42, 45–48, 50 and 55; p < 0.05; Fig. 3). 
3.4. Colonoscopically-assessed parameters 
AOM/DSS mice presented with severe colitis as determined by co-
lonoscopy on days 20, 41 and 62 (p < 0.05; Fig. 4a). Saireito, Emu Oil 
and the combination of Emu Oil/Saireito significantly reduced colitis 
severity scores on days 20 and 4, compared to AOM/DSS controls, with 
no effect exhibited by treatments on day 62 (p < 0.05; Fig. 4a). 
Furthermore, Emu Oil/Saireito in combination further decreased colitis 
severity scores in comparison with both Saireito and Emu Oil alone on 
day 20 (p < 0.05; Fig. 4a). 
Colonic tumours were evident in all AOM/DSS mice. AOM/DSS 
controls presented with the highest number of colonic tumours at all 
time-points of the trial (p < 0.05; Fig. 4b). Emu Oil-administration 
significantly decreased the number of tumours on day 20 compared to 
AOM/DSS controls (p < 0.05; Fig. 4b). Saireito alone did not signifi-
cantly impact tumour development at any time-point; however, the 
combination of Emu Oil/Saireito significantly reduced tumour burden 
on day 41 of the trial (p < 0.05; Fig. 4b), with no effect observed on 
other days. Finally, Emu Oil/Saireito further decreased tumour number 
compared to Saireito alone on days 20 and 62 (p < 0.05; Fig. 4b); with 
no further effect compared to Emu Oil alone (p > 0.05). 
3.5. Burrowing 
In normal mice, Saireito, Emu Oil or combined Emu Oil/Saireito did 
not significantly impact burrowing ability on the days analysed 
(p > 0.05). AOM/DSS impaired burrowing activity on days 19 and 40 
compared to saline controls (p < 0.05; Fig. 5), with no effect exhibited 
on day 61. Administration of Saireito alone significantly increased 
burrowing activity of AOM/DSS mice on day 19 compared to AOM/DSS 
controls (p < 0.05; Fig. 5). Emu Oil and the combination of Emu Oil/ 
Saireito did not affect burrowing behaviour of AOM/DSS mice during 
the experimental trial. 
3.6. Nesting behaviour 
In normal mice, positive nesting behaviour was evident in all treat-
ment groups (1 ± 0). Furthermore, AOM/DSS did not affect nesting 
ability as all mice successfully building nests (1 ± 0). Administration of 
Saireito and Emu Oil, alone and in combination, had no effect on nest 
building compared to AOM/DSS controls (1 ± 0; p > 0.05). 
Fig. 1. Secretion of IL-12p40 and IL-10 by 
mature dendritic cells. Dendritic cells were 
matured with IL-1β, TNF-α and LPS for 24 h in 
the absence (negative) or presence of Saireito, 
Emu Oil or the combination of Emu Oil and 
Saireito at the concentration of 2 µg/ml. The 
concentrations of IL-12p40 and IL-10 in the 
supernatants were determined by ELISA. The 
data are presented as SI, i.e. the concentration 
of each cytokine in the supernatant of cells in 
the presence of the nutraceutical divided by the 
concentration of the cytokine in the superna-
tant of cells in the absence of the nutraceutical. 
Data are expressed as mean ± SEM (n = 2 do-
nors). **p < 0.01, *p < 0.05 compared to 
negative.   
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3.7. Intestinal permeability (FITC-dextran) 
FITC-dextran concentrations (ug/ml) were unchanged in AOM/DSS 
mice compared to normal controls (p > 0.05; Fig. 6). Moreover, Saireito, 
Emu Oil and combined Emu Oil/Saireito did not impact intestinal 
permeability in comparison with AOM/DSS controls (p > 0.05; Fig. 6). 
Fig. 2. Daily bodyweight change of (a) Saline mice, (b) Saline and AOM/DSS controls and (c) AOM/DSS mice. Data are expressed as mean (% starting 
bodyweight) ± SEM (n = 10/group). * **p < 0.001, * *p < 0.01, *p < 0.05 compared to Saline + Water + Water; ^^^p < 0.001, ^^p < 0.01, ^p < 0.05 compared to 
AOM + DSS + Water; ###p < 0.001, ##p < 0.01, #p < 0.05 compared to AOM + DSS + Saireito; $$$p < 0.001, $$p < 0.01, $p < 0.05 compared to 
AOM + DSS + Emu Oil on the same day. 
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Fig. 2. (continued). 
Fig. 3. Daily Disease Activity Index (DAI) score. Data are expressed as mean ± SEM (n = 10/group). ***p < 0.001, **p < 0.01, *p < 0.05 compared to Sali-
ne + Water + Water; ^^^p < 0.001, ^^p < 0.01, ^p < 0.05 compared to AOM + DSS + Water; ###p < 0.001, ##p < 0.01, #p < 0.05 compared to 
AOM + DSS + Saireito; $$$p < 0.001, $$p < 0.01, $p < 0.05 compared to AOM + DSS + Emu Oil on the same day. 
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3.8. Intestinal and visceral organ measurements 
In normal animals, weights of the visceral organs and intestinal 
lengths/weights remained unaffected by administration of Emu Oil, 
Saireito and the combination of Emu Oil/Saireito (p > 0.05; Table 1). 
AOM/DSS mice presented with significantly increased colonic weights 
compared to saline controls (p < 0.05; Table 1), with no effect exhibited 
by Emu Oil, Saireito or the combined treatment (p > 0.05). Further-
more, colonic shortening was evident in AOM/DSS controls in com-
parison with saline controls (p < 0.05; Table 1). Finally, weights of the 
liver and spleen were increased in AOM/DSS control mice compared to 
saline controls (p < 0.05; Table 1), with no effect exhibited by Emu Oil, 
Saireito or the combination of Emu Oil/ Saireito (p > 0.05). All other 
visceral organ weights remained unaffected in AOM/DSS mice (Table 1). 
3.9. Gross tumour morphology 
Mice treated with AOM/DSS presented with significant distal colonic 
tumours (Fig. 7). At kill (day 63) Emu Oil and Saireito-treatment alone 
did not significantly impact tumour sizes or overall tumour number 
(p > 0.05; Fig. 8). The numbers of large tumours in Emu Oil, Saireito 
and the combination of Emu Oil/Saireito treatment groups were less 
than in AOM/DSS controls; however, this did not achieve statistical 
significance. Finally, the combination of Emu Oil/Saireito significantly 
reduced the number of small colonic tumours (diameter < 2 mm) and 
the overall number of tumours compared to AOM/DSS controls 
(p < 0.05; Fig. 8). 
Fig. 4. Colonoscopically-assessed (a) colitis severity and (b) tumour development. Data are expressed as mean (colitis severity score or tumour number) ± SEM 
(n = 10/group). ***p < 0.001, compared to Saline + Water + Water; ^^^p < 0.001, ^^p < 0.01, ^p < 0.05 compared to AOM + DSS + Water; ###p < 0.001, 
##p < 0.01, #p < 0.05 compared to AOM + DSS + Saireito; $$$p < 0.001 compared to AOM + DSS + Emu Oil on the same day. 
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3.10. Histologically-assessed disease severity 
In the proximal colon, there were no significant differences in 
histologically-assessed severity scores across experimental groups 
(p > 0.05; Fig. 9). However, AOM/DSS controls presented with signifi-
cant damage and increased histological severity scores in the distal 
colon compared with normal controls (p < 0.05; Fig. 9). Neither Emu 
Oil nor Saireito-treatment impacted histologically-assessed severity 
scores in the distal colon (p > 0.05). 
4. Discussion 
In the current study, the combination of Emu Oil and the herbal 
formula Saireito decreased disease severity in mice with experimentally- 
induced CA-CRC. Clinical indicators including bodyweight attenuation, 
DAI, colonoscopically-assessed inflammation and tumour burden were 
improved by the combined treatment to a greater extent than Emu Oil or 
Saireito alone. Importantly, in normal mice, administration of Emu Oil/ 
Saireito or each nutraceutical alone, did not result in any adverse side- 
effects during the nine-weeks of treatment. Minor weight gain and a 
slightly increased DAI score was evident in normal control mice treated 
with Emu Oil and Saireito alone; however, this was only observed on a 
few days throughout the 63-day study and was therefore deemed to be of 
negligible significance. 
Colonoscopy procedures are crucial in the diagnosis and monitoring 
of humans with IBD and CRC; however, only in the past twenty years has 
it been executable in pre-clinical mouse models [36,37]. Additional to 
mimicking both human monitoring and diagnosis techniques, the colo-
noscopy procedure is advantageous during long-term mouse trials as it 
allows researchers to obtain greater amounts of data during in vivo 
studies with a singular end-point. Furthermore, colonoscopies may also 
identify when pathogenesis is progressing rapidly or severely, early 
Fig. 5. Burrowing ability of mice. Data are expressed as mean (amount burrowed) ± SEM (n = 10/group). ***p < 0.001, *p < 0.05 compared to Sali-
ne + Water + Water; ^^p < 0.01 compared to AOM + DSS + Water on the same day. 
Fig. 6. Intestinal permeability assessed by FITC-dextran levels. Data are expressed as mean serum FITC-dextran (µg/ml) ± SEM (n = 10/group).  
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enough for interventions to be implemented without impacting animal 
welfare. In the current study, and previous AOM/DSS investigations [14, 
38–40], colonoscopies were performed at three time-points at the end of 
each DSS/water cycle. The nutraceuticals administered in the current 
study were protective against colitis, with the combination of Emu Oil 
and Saireito offering greater protection compared to the treatments 
alone. Interestingly, these protective effects were only observed at the 
first two colonoscopy time-points (days 20 and 41), with no effect 
determined on the final procedure (day 62). However, this was not an 
unexpected finding as the parameters defining colitis severity score 
assess tissue void of tumours, which inevitably becomes progressively 
sparse as CRC development is more pronounced [31]. At the final co-
lonoscopy time-point, tumours are often very large and occupy a large 
circumference of the video diameter, and in severe cases, are almost 
unpassable. Nonetheless, colonoscopically-assessed colorectal tumours 
were significantly decreased by Emu Oil and the combination of Emu Oil 
and Saireito, with the combination resulting in the greatest reduction in 
tumour number. Notably, these results were reflected in tumour 
assessment at time of euthanasia, whereby the combination of Emu Oil 
and Saireito decreased the number of small colonic tumours and overall 
tumour development. Additionally, future studies should aim to char-
acterise the tumours formed to indicate whether they are hyperplastic 
polyps, adenomatous polyps, polyps with dysplasia or other, as this may 
assist in preventing neoplasia. 
Although Emu Oil has previously been investigated in CA-CRC [14], 
the present study is the first to investigate the Japanese Kampo formula, 
Saireito, in the AOM/DSS model. Gastrointestinal tumours are the most 
common cause of cancer-related death in Japan and Kampo formulae, 
including Juzentaihoto, Daikenchuto, Hocheuekkito and Shosaikoto, 
have been investigated in randomized clinical trials of such cancers 
[41–43]. Kato et al. investigated the efficacy of Saireito in 5-Flourouracil 
(5-FU)-induced mucositis in comparison with Daikenchuto [44]. Similar 
to that observed in the current study, Saireito-administration signifi-
cantly protected against bodyweight loss and diarrhoea compared to 
5-FU controls [44]. Furthermore, twice-daily administration of Saireito 
dose-dependently (100–1000 mg/kg) improved histologically-assessed 
morphological changes, including villus shortening and crypt disrup-
tion that were induced by 5-FU [44]. Daikenchuto was also effective at 
improving these histological parameters but to a lesser effect than 
Saireito. However, in the current study, there were no significant im-
pacts of Saireito or Emu Oil on histologically-assessed disease severity, 
although villus height and crypt disruption were not investigated as 
individual parameters. 5-FU also caused an upregulation of TNF-alpha 
and IL-1beta mRNA that was attenuated by Saireito at a dose of 
1000 mg/kg [44]. Furthermore, in the Kato study, tumour growth 
following implantation was reduced by 5-FU without a specific effect of 
Saireito on tumourigenesis. Importantly, Saireito significantly decreased 
diarrhoea and bodyweight loss caused by the chemotherapeutic agent 
[44], an effect that was also observed in the present study. Additionally, 
analysis of the microbiome collected from faecal samples using shotgun 
metagenomics would be beneficial in understanding the mechanism of 
action and the effect that Emu Oil and Saireito have on species and 
abundance of microbioata in AOM/DSS mice. Faecal samples collected 
as part of routine daily measurements could also be investigated for 
lipcalin2, a marker of inflammation throughout the 9-week experi-
mental timeline. 
The Chinese herbal medicine Panax notoginseng and American 
ginseng (Panax quinquefolius L.) have previously increased the anti- 
tumour effects of chemotherapy and been investigated in AOM/DSS 
induced CA-CRC [45,46]. American ginseng decreased colitis severity, 
DAI and histological severity during the acute pre-neoplastic stage of the 
study, and later supressed tumour multiplicity [45]. Wang et al. [45] 
highlighted that tumour suppression was linked to attenuation of the 
inflammatory-associated cytokines, IL-1α, IL-1β and IL-6. IL-6 is pro-
posed to be involved in the pathogenesis of IBD and CRC by direct 
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through activation of the STAT3 pathway, thus creating a 
tumour-promoting microenvironment [47,48]. This is largely supported 
by a study whereby IL-6 knockout mice presented with significantly 
reduced tumour growth in a STAT3 dependent manner [49]. Addition-
ally, IL-12 and lack of IL-10 have been implicated in the pathogenesis of 
colitis and specifically, IL-10 deficient mice can develop UC and CRC just 
weeks after birth [50]. In the current study, the effects of Emu Oil and 
Saireito on secretion of IL-12p40 and IL-10 from mDCs were analysed in 
vitro. Cells treated with Emu Oil and the combination of Emu Oil and 
Saireito exhibited potent anti-inflammatory potential by reducing the 
secretion of the pro-inflammatory cytokine IL-12p40; an effect that was 
not observed following treatment of Saireito alone. Moreover, the 
anti-inflammatory cytokine IL-10 was unaffected by nutraceutical 
treatment. Future investigations should determine the effects of the 
selected nutraceuticals on IL-12, IL-10 and IL-6 in intestinal tissue 
collected as biopsies during colonoscopy procedures or at time of kill in 
CA-CRC animal studies. Novel therapies could then be developed to 
target IL-6 as a primary mediator for inflammation-associated carcino-
genesis. Furthermore, in vitro techniques including the MTT-assay for 
cell viability of Caco-2 (colorectal cancer) and healthy intestinal cells, 
would provide evidence of any direct toxic effect of neoplastic cells by 
Emu Oil and Saireito. 
Techniques that monitor pain, stress and daily-living behaviour are 
important in laboratory animal studies in order to evaluate how disease 
or treatments are impacting overall animal well-being [51]. Recently, 
DAI, facial grimace and burrowing were assessed and compared in 
CA-CRC mice [52]. It was concluded, that DAI was the most reliable 
method of welfare evaluation in this model of chronic gastrointestinal 
disease [52]. In the present study, burrowing and nesting techniques 
were utilised, whereby there was a significant improvement in 
Fig. 7. Photos of longitudinally-opened mouse colons taken at time of euthanasia.  
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burrowing activity of AOM/DSS mice treated with Saireito on day 19 of 
the trial. However, nesting behaviour was not impacted in AOM/DSS 
mice compared to normal controls or by nutraceutical treatment. 
Although the present study scored nesting using the simplest scoring 
method of a zero for no nest and a one for a successful nest built, future 
studies in the AOM/DSS model could evaluate nesting in a more com-
plex format using methods described by Deacon et al. and Paumier et al. 
[53,54]. Moreover, hoarding and judgement bias techniques may also be 
of interest in the AOM/DSS model [53,55]. 
In conclusion, the combination of Emu Oil and Saireito represents a 
promising adjuvant treatment to conventional CA-CRC treatments. This 
combination improved clinical indicators of CA-CRC while reduced 
numbers of colonic tumours. However, further investigation into the 
effects of these nutraceuticals on inflammatory-associated cytokines, 
such as IL-6, linked to the pathogenesis of CA-CRC and microbial anal-
ysis of faecal samples is crucial to understand the mechanism by which 
Emu Oil and Saireito exert their beneficial action in combination. 
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Fig. 8. Tumour number obtained from longitudinally-opened colons. Data are expressed as mean (tumour number) ± SEM (n = 10/group). Colonic tumours 
with a diameter < 2 mm were determined as ‘small’, 2–3 mm as ‘medium’ and a diameter of > 3 mm was ‘large’. ***p < 0.001, **p < 0.01, *p < 0.05 compared to 
Saline + Water + Water; ^p < 0.05 compared to AOM + DSS + Water; #p < 0.05 compared to AOM + DSS + Saireito. 
Fig. 9. Histologically-assessed disease severity scores of the proximal and distal colon. Data are expressed as mean (severity score) ± SEM (n = 10/group). 
***p < 0.001 compared to Saline + Water + Water. 
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